Literature DB >> 24494617

Multifunctional nucleic acids for tumor cell treatment.

Monika Pofahl1, Jesper Wengel, Günter Mayer.   

Abstract

We report on a multifunctional nucleic acid, termed AptamiR, composed of an aptamer domain and an antimiR domain. This composition mediates cell specific delivery of antimiR molecules for silencing of endogenous micro RNA. The introduced multifunctional molecule preserves cell targeting, anti-proliferative and antimiR function in one 37-nucleotide nucleic acid molecule. It inhibits cancer cell growth and induces gene expression that is pathologically damped by an oncomir. These findings will have a strong impact on future developments regarding aptamer- and antimiR-related applications for tumor targeting and treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24494617      PMCID: PMC3962646          DOI: 10.1089/nat.2013.0472

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  24 in total

1.  Vertebrate microRNA genes.

Authors:  Lee P Lim; Margaret E Glasner; Soraya Yekta; Christopher B Burge; David P Bartel
Journal:  Science       Date:  2003-03-07       Impact factor: 47.728

Review 2.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

3.  Making sense of therapeutics using antisense technology.

Authors:  Ravinder Malik; Ipsita Roy
Journal:  Expert Opin Drug Discov       Date:  2011-03-16       Impact factor: 6.098

4.  Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.

Authors:  Jiehua Zhou; Haitang Li; Jane Zhang; Swiderski Piotr; John Rossi
Journal:  J Vis Exp       Date:  2011-06-23       Impact factor: 1.355

5.  Aptamer:toxin conjugates that specifically target prostate tumor cells.

Authors:  Ted C Chu; John W Marks; Laura A Lavery; Sarah Faulkner; Michael G Rosenblum; Andrew D Ellington; Matthew Levy
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

6.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

Review 7.  AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia.

Authors:  Fabien Mongelard; Philippe Bouvet
Journal:  Curr Opin Mol Ther       Date:  2010-02

8.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.

Authors:  Omid C Farokhzad; Jianjun Cheng; Benjamin A Teply; Ines Sherifi; Sangyong Jon; Philip W Kantoff; Jerome P Richie; Robert Langer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-10       Impact factor: 11.205

9.  Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.

Authors:  Robert E Lanford; Elisabeth S Hildebrandt-Eriksen; Andreas Petri; Robert Persson; Morten Lindow; Martin E Munk; Sakari Kauppinen; Henrik Ørum
Journal:  Science       Date:  2009-12-03       Impact factor: 47.728

Review 10.  OncomiRs: the discovery and progress of microRNAs in cancers.

Authors:  William C S Cho
Journal:  Mol Cancer       Date:  2007-09-25       Impact factor: 27.401

View more
  8 in total

Review 1.  Targeting noncoding RNAs in disease.

Authors:  Brian D Adams; Christine Parsons; Lisa Walker; Wen Cai Zhang; Frank J Slack
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

Review 2.  Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology.

Authors:  Martin Panigaj; M Brittany Johnson; Weina Ke; Jessica McMillan; Ekaterina A Goncharova; Morgan Chandler; Kirill A Afonin
Journal:  ACS Nano       Date:  2019-11-05       Impact factor: 15.881

Review 3.  Oligonucleotide Therapies: The Past and the Present.

Authors:  Karin E Lundin; Olof Gissberg; C I Edvard Smith
Journal:  Hum Gene Ther       Date:  2015-08-03       Impact factor: 5.695

Review 4.  Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy.

Authors:  Lukas J Aaldering; Hossam Tayeb; Shilpa Krishnan; Susan Fletcher; Stephen D Wilton; Rakesh N Veedu
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

5.  Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.

Authors:  Sif Holmboe; Pernille Lund Hansen; Helge Thisgaard; Ines Block; Carolin Müller; Niels Langkjær; Poul Flemming Høilund-Carlsen; Birgitte Brinkmann Olsen; Jan Mollenhauer
Journal:  PLoS One       Date:  2017-05-22       Impact factor: 3.240

6.  Development of a Novel DNA Oligonucleotide Targeting Low-Density Lipoprotein Receptor.

Authors:  Tao Wang; Kamal Rahimizadeh; Rakesh N Veedu
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-16       Impact factor: 8.886

Review 7.  Selection and Biosensor Application of Aptamers for Small Molecules.

Authors:  Franziska Pfeiffer; Günter Mayer
Journal:  Front Chem       Date:  2016-06-15       Impact factor: 5.221

8.  Modular Assembly of Cell-targeting Devices Based on an Uncommon G-quadruplex Aptamer.

Authors:  Felipe Opazo; Laura Eiden; Line Hansen; Falk Rohrbach; Jesper Wengel; Jørgen Kjems; Günter Mayer
Journal:  Mol Ther Nucleic Acids       Date:  2015-09-01       Impact factor: 10.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.